Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Clark

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Experimental Hematology|September 22, 2010
Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressiveJose M Rojas, Lihui Wang, Sally Owen, et al.
Leukemia Research|December 17, 2009
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatographyAndrea Davies, Alison K Hayes, Katy Knight, et al.
Leukemia Research|June 25, 2010
BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patientsJosé M Rojas, Katy Knight, Sarah Watmough, et al.
British Journal of Haematology|November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remissionMark W Drummond, David Marin, Richard E Clark, et al.
British Journal of Haematology|January 14, 2010
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemiaClaire M Lucas, Robert J Harris, Athina Giannoudis, et al.
Blood|April 15, 2011
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionClaire M Lucas, Robert J Harris, Athina Giannoudis, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?Catherine L Riley, Morgan G Mathieu, Richard E Clark, et al.
Frontiers in Oncology|December 26, 2022
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessationElena Karg, Christoph Baldow, Thomas Zerjatke, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2009
Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responsesSylvie Rusakiewicz, Geraldine Aubert, Richard E Clark, et al.
Leukemia Research|October 30, 2010
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinibZahra Raisi Estabragh, Katy Knight, Sarah J Watmough, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Experimental Hematology|September 22, 2010
Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressiveJose M Rojas, Lihui Wang, Sally Owen, et al.
Leukemia Research|December 17, 2009
Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatographyAndrea Davies, Alison K Hayes, Katy Knight, et al.
Leukemia Research|June 25, 2010
BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patientsJosé M Rojas, Katy Knight, Sarah Watmough, et al.
British Journal of Haematology|November 18, 2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remissionMark W Drummond, David Marin, Richard E Clark, et al.
British Journal of Haematology|January 14, 2010
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemiaClaire M Lucas, Robert J Harris, Athina Giannoudis, et al.
Blood|April 15, 2011
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progressionClaire M Lucas, Robert J Harris, Athina Giannoudis, et al.
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?Catherine L Riley, Morgan G Mathieu, Richard E Clark, et al.
Frontiers in Oncology|December 26, 2022
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessationElena Karg, Christoph Baldow, Thomas Zerjatke, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2009
Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responsesSylvie Rusakiewicz, Geraldine Aubert, Richard E Clark, et al.
Leukemia Research|October 30, 2010
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinibZahra Raisi Estabragh, Katy Knight, Sarah J Watmough, et al.
Pageof 12